Macrobac

Quick links to important sections

Macrobac

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Macrobac

Quick Facts

Property Description
Active Ingredient Azithromycin
Forms Tablet, capsule, oral suspension, IV solution
Pharmacological Class Macrolide Antibiotic (Azalide)
General Purpose To halt the growth of susceptible bacteria
Origin Semi-synthetic

What is Macrobac and What Type of Medicine is it?

Macrobac is a prescription-only medication whose active component is Azithromycin, classified as a macrolide antibiotic. More specifically, it belongs to the azalide subclass, which features a unique chemical structure that imparts high acid stability, simplifying its primary oral administration for systemic effect. Azithromycin is a semi-synthetic derivative of erythromycin, engineered to possess favorable properties such as a long half-life. This long half-life is a key feature, enabling shorter treatment regimens compared to earlier macrolides.


Macrobac's Active Composition and Available Forms

The active composition of Macrobac is the single ingredient Azithromycin, typically formulated as the dihydrate salt to optimize stability and bioavailability. This compound is combined with various pharmaceutical excipients—such as binders and fillers—necessary for the final physical preparations. Macrobac is available in multiple dosage forms, including the common film-coated tablet and capsule, as well as a powder for oral suspension, which is a distinguishing feature that makes it suitable for pediatric patients and others who may have difficulty swallowing solids.


What is the General Purpose of This Antibiotic?

The general purpose of Macrobac is to provide targeted support against systemic bacterial infections caused by susceptible organisms. Azithromycin works to stop the growth of bacteria, a mechanism that serves to reduce the overall burden of infection in the body. This antimicrobial function assists the body's immune system to clear the pathogen and resolve the infectious process, characterizing the drug's role as an agent for fighting specific types of bacterial infections.

Regulatory References

  1. U.S. National Library of Medicine (NIH)

What side effects are possible with Macrobac?

Possible Side Effects and Safety Information

The official safety profile for Macrobac (Azithromycin) is structured around categories that classify potential adverse reactions and special safety warnings, as documented in regulatory sources such as the FDA and EMA.

Frequency-Classified Adverse Reactions

The most frequently reported adverse reactions affect the Gastrointestinal System. Diarrhea and Nausea are classified as common or very common, often accompanied by abdominal pain and vomiting. Other common effects include headache and certain changes in laboratory findings.

Serious Adverse Reactions

Official regulatory labeling highlights the potential for rare but serious adverse reactions across several physiological systems. These include Prolongation of the QT Interval and Torsades de pointes, which are irregular heart rhythms that can be fatal. Severe, sometimes fatal Hepatotoxicity (liver damage), including hepatic failure and cholestatic jaundice, has been reported. Serious hypersensitivity reactions and severe skin reactions (such as SJS, TEN, and DRESS) are also documented warnings.

Population-Specific Safety Notes

Specific warnings apply to certain populations. The drug is contraindicated in individuals with a known hypersensitivity to macrolides or a history of cholestatic jaundice or hepatic dysfunction associated with prior use of Azithromycin. Neonates (infants up to 42 days old) face a specific risk of Infantile Hypertrophic Pyloric Stenosis (IHPS), and elderly patients may be more susceptible to the cardiac risk of Torsades de pointes. The risk of acute cardiovascular death was noted to be greater during the first five days of use.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information describes Macrobac (Azithromycin) overdose primarily through the exacerbation of known adverse reactions. In cases where doses higher than recommended are taken, patients typically experience severe Gastrointestinal symptoms, including Nausea, Vomiting, and Diarrhea.


Documented Severe Outcomes and Required Actions

The most serious risk cited in official labeling is the potential for cardiotoxicity. Overdose carries a risk of Prolongation of the QT interval and subsequent fatal cardiac arrhythmias, specifically Torsades de pointes.

Severe Risk Required Action
Life-threatening cardiac arrhythmia Seek immediate medical attention
Severe Gastrointestinal symptoms Symptomatic and supportive measures

When overdose is suspected, immediate medical attention or contact with emergency services is required, particularly if signs of heart rhythm disturbances—such as dizziness, fainting, or irregular heartbeat—are present.

Treatment management for Macrobac overdose relies entirely on general symptomatic and supportive measures as no specific antidote is known. Due to the drug's long half-life, hospital monitoring and prolonged observation may be necessary to manage potential complications. Elderly patients are noted as a population at higher risk for the arrhythmogenic effects.

Therapeutic Uses of Macrobac

What Macrobac Treats: Main Uses and Benefits

Macrobac (Azithromycin) is commonly used to help manage infections caused by susceptible bacteria across several key areas of the body. The medication is relevant for addressing conditions presenting with systemic or localized discomfort, primarily focused on acute episodes.

It is applied across domains where additional symptomatic support is needed, particularly for acute episodes like community-acquired pneumonia, acute bacterial exacerbations of chronic bronchitis, and acute otitis media. It also plays a role in managing specific uncomplicated skin and skin structure infections, as well as urethritis and cervicitis caused by bacteria like Chlamydia.

“The medication is often utilized in contexts where symptoms create noticeable physiological strain, offering support to ease the overall burden.”

The primary goal may be part of symptomatic management for conditions presenting with systemic or localized discomfort. It helps address symptom clusters that may become intense or disruptive, such as increased cough, ear pain, or localized swelling. Macrobac is also considered relevant as an alternative for patients with penicillin allergies, assisting with maintaining functional stability during symptomatic phases.

Quick Fact: Relief for Acute Discomfort
Symptom Management Focus: Infections characterized by localized pain, increased sputum production, and acute inflammation.
Primary Patient Benefit: Contributes to easing the overall symptom load during symptomatic phases.
Common Scenario: Acute episodes of otitis media and uncomplicated chlamydial infections.

Eligibility and Restrictions for Use

Who Can and Cannot Use Macrobac?

Macrobac (Azithromycin) eligibility is strictly defined by regulatory documents, focusing on age, patient history, and co-existing medical conditions.

Contraindicated Populations (Must Not Use) Age-Related Eligibility Rules
Patients with known hypersensitivity to Azithromycin or any macrolide/ketolide antibiotic. Safety is not established in infants under 6 months for most uses.
Patients with a history of cholestatic jaundice or liver dysfunction from prior Macrobac use. Pharyngitis/Tonsillitis use is not established in children under 2 years.

Restricted and Conditional Use

Organ Function: Caution is mandatory in patients with severe renal impairment (GFR <10 mL/min) and in those with significant hepatic disease [2.2, 2.3]. Patients with mild-to-moderate impairment are eligible for standard use. Cardiovascular Risk: Use requires caution in patients with pre-existing conditions like QT prolongation or uncorrected low potassium levels due to the risk of cardiac arrhythmia [1.2, 4.5]. Pregnancy/Lactation: Use during pregnancy and breastfeeding is conditional, permitted only if clearly needed and when the benefit outweighs the potential risk, as Macrobac is present in human milk [3.3].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents classify Macrobac (Azithromycin) interactions based on their mechanism and resulting constraints. Unlike some older macrolides, Macrobac is generally considered to have a limited direct interaction profile with the major hepatic cytochrome P450 enzymes.

Documented Interaction Patterns

Interaction Type Interacting Substance/Class Official Constraint/Outcome
Formal Contraindication Ergot Derivatives (e.g., Ergotamine), Pimozide These combinations are prohibited due to significant risk of adverse events, such as ergotism or QTc prolongation.
Pharmacodynamic Risk Drugs that prolong the QTc Interval Co-administration carries an additive risk of QTc interval prolongation, as stated in prescribing information.
Exposure Modification Nelfinavir (Antiviral) Co-administration results in significantly increased systemic exposure to Macrobac, requiring monitoring for Macrobac adverse reactions.
Anticoagulant Effect Warfarin and Coumarin Anticoagulants May increase coagulation times, mandating regulatory monitoring of Prothrombin Time (PT) and INR.

Timing and Population Notes

Interactions with Antacids (aluminum/magnesium hydroxide) are pharmacokinetic, leading to a 24% reduction in peak concentration ( C max). Therefore, official product labels mandate that Macrobac and antacids must be separated by an interval of approximately two hours. In patients with severe renal impairment ( GFR < 10 mL/ min), a 33% increase in Azithromycin exposure has been documented, which may affect the overall interaction risk.

Mechanism of Action

Macrobac's mechanism of action is primarily defined by its role as an inhibitor of bacterial protein synthesis. The active compound, Azithromycin, achieves this by selectively binding to the 23S ribosomal RNA component of the bacterial 50S ribosomal subunit. This precise molecular interaction physically blocks the nascent polypeptide exit tunnel, preventing the vital process of protein chain elongation and translocation. This interference halts the growth of susceptible bacterial populations, inducing bacteriostasis, a physiological change that stabilizes the pathogen burden and supports the host immune clearance process.

A secondary mechanistic domain involves modulation of host inflammatory pathways. The compound accumulates within immune cells, such as macrophages and neutrophils, influencing their signaling to regulate the release of pro-inflammatory mediators. The efficacy of this mechanism is constrained by bacterial counter-mechanisms, specifically ribosomal methylation and active efflux pump proteins, which prevent effective drug binding and lead to subsequent uncontrolled bacterial growth.

Dosage and Administration Information

How to Use Macrobac (Azithromycin) - Official Administration Guidelines

Macrobac is used according to specific, high-level guidelines that define its administration route, dosage, frequency, and duration patterns.

Administration Scope

Entity Instruction
Route of Administration Primarily Oral (tablets, capsules, suspension). Also available for Intravenous (IV) Infusion for initial therapy in certain severe adult infections.
Dosing Schedule (Adults) Standard 5-Day Course: 500 mg on Day 1, followed by 250 mg once daily on Days 2-5. 3-Day Course: 500 mg once daily for 3 days. Single Dose: 1 g (1,000 mg) or 2 g (2,000 mg) for specific infections.
Timing in Relation to Meals Standard Forms: May be taken with or without food. Extended-Release Suspension (2 g): Must be taken on an empty stomach (at least 1 hour before or 2 hours after a meal).
Age-Group Administration Adults and Older Adults: Standard adult doses apply. Pediatric Patients (< 45 kg): Dosing is weight-based (mg/kg) using the oral suspension.
Missed-Dose Rules If the missed dose is 12 hours or less late, take it immediately. If more than 12 hours have passed, skip the missed dose and resume the regular schedule.

Resulting Procedural Structure

The instructions establish a clear, standardized pattern for Macrobac's use. The administration is generally once daily for multi-day regimens, reflecting the drug’s long half-life. IV infusion must be given slowly over 1 to 3 hours, and IV bolus is prohibited. Furthermore, the instructions mandate separation from antacids and detail the need for weight-based dosing when used in pediatric populations, ensuring clinical consistency.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Macrobac (Azithromycin)

Evidence Overview for Respiratory Tract Infections

Research exploring Macrobac's role in respiratory tract infections often takes the form of Randomized Controlled Trials (RCTs). These studies are used in research exploring how symptoms change over time and measuring short-term outcomes related to systemic or functional imbalance in patients.

Evidence Structure for Community-Acquired Pneumonia (CAP)

Macrobac was studied for use in Community-Acquired Pneumonia. Researchers conducted large-scale comparative trials that included both hospitalized and non-hospitalized adults, as well as children. These studies monitored outcomes related to systemic or functional imbalance, such as measurements related to fever reduction, changes in general physical condition, and monitoring for pathogen clearance.

Evidence Structure for Acute Exacerbations of Chronic Bronchitis (ABECB)

Macrobac was evaluated in patients experiencing acute exacerbations of chronic bronchitis. Comparative trials explored short-term symptom changes by measuring patient-reported outcomes describing perceived discomfort, such as changes in cough severity and sputum production. While research describes patterns related to symptom change, the evidence exploring long-term or preventative use in maintaining functional stability is limited.


Evidence for Pediatric and Localized Infections

Research exploring Macrobac's application in localized infections, particularly those in children, often focuses on regimens evaluated against standard antibiotic courses.

Evidence Structure for Acute Otitis Media (AOM)

Macrobac was studied for use in acute otitis media in pediatric patients. The research predominantly consists of RCTs where short-course regimens were evaluated in trials. Outcomes measured included outcomes related to physical discomfort (ear pain, fever) and the need for subsequent antibiotic courses.

Evidence Structure for Uncomplicated Skin and Soft Tissue Infections

Research has examined Macrobac for use in uncomplicated infections of the skin. Trials measured endpoints related to outcomes linked to inflammatory or irritative states, such as changes in swelling, affected area dimensions, and systemic fever. The results apply only to the populations studied, meaning the evidence base does not provide context for managing severe, complicated infections.


Uncertainties and Areas for Future Research

While a body of research exists, there are several areas where certainty remains low. A major concern that continues to be examined across the research landscape is the rising incidence of antimicrobial resistance among various bacteria, which may impact future outcomes. Additionally, follow-up durations were limited in many primary trials, leaving long-term effects and the full impact on chronic functional health not fully established.

Key Studies & References Label: AZITHROMYCIN tablet, film coated (DailyMed - NIH)

Frequently Asked Questions (FAQ)

Common questions about Macrobac (FAQ)

Q: How long does a course of Macrobac treatment usually last?

Official regulatory documents describe several common treatment regimens for Macrobac, with the duration depending on the specific infection being addressed. The most frequent patterns include a 5-day course, a 3-day course, or a single dose regimen for certain conditions. The choice of regimen is determined by a healthcare provider based on the type of infection and individual considerations.

Q: Are there any major food groups or supplements that interfere with Macrobac?

Official product information notes that Macrobac’s absorption is reduced when taken with Antacids containing aluminum or magnesium; therefore, these must be separated by approximately two hours. The high-strength extended-release oral suspension is specifically labeled to be taken on an empty stomach. Standard tablet forms are generally permitted with or without food.

Q: Do official patient information leaflets describe any psychological or mood effects?

Yes, official safety information documents list certain Central Nervous System effects as potential side effects. These include reports of nervousness and insomnia (sleep problems). This information is provided to describe the drug's known profile.

Q: Why do official documents emphasize taking Macrobac for the full duration?

Regulatory guidance stresses adherence to the full prescribed duration because it is necessary to support the drug's therapeutic action. Completing the entire course helps to ensure the intended effect is reached and assists in preventing the potential for a relapse of the infection.

Q: Does Macrobac have an effect on kidney or liver function, according to official reports?

Official reports document the potential for rare but serious adverse reactions affecting the liver, known as hepatotoxicity (liver damage), including hepatic failure. Furthermore, caution is mandated in individuals with severe renal impairment (severe kidney problems), as this can lead to increased drug exposure in the body. Abnormalities in liver enzymes have also been reported.

Q: Are there any official warnings about driving or operating machinery while on Macrobac?

Safety documents list potential side effects such as dizziness or effects related to an irregular heart rhythm that could cause fainting. These conditions may affect concentration or physical ability, which is a consideration for tasks such as driving or operating machinery.

Q: Can women who are pregnant or breastfeeding use Macrobac?

Use during both pregnancy and breastfeeding is described in regulatory documents as conditional. Its use is permitted only when a healthcare provider determines the potential benefit outweighs the potential risk. Official information confirms the drug is known to be present in human milk.

Q: Can Macrobac be taken with common pain relievers like Tylenol (acetaminophen)?

The regulatory information does not list acetaminophen (Tylenol) as a major drug interaction requiring a formal constraint or prohibition. Known drug-drug interaction warnings are detailed in the official product information.

Q: Can Macrobac affect sleep patterns?

Yes, official safety information lists insomnia (trouble sleeping) as a documented side effect of the medication. This is a recognized adverse reaction that is described in the drug's safety profile.

Q: Is Macrobac considered safe for older adults?

Official information suggests studies have not identified geriatric-specific problems that would limit its use. However, regulatory warnings note that older adults may be more susceptible to the cardiac risk of a rare, serious irregular heart rhythm known as Torsades de pointes.

Q: Do studies suggest Macrobac is a long-term or short-term treatment option?

Macrobac is most often used as a short-term treatment involving multi-day courses. However, regulatory documents also detail protocols for long-term therapy (for example, 6 to 12 months or longer) in patients with certain chronic respiratory conditions.

Q: Are there any known interactions between Macrobac and caffeine or alcohol?

Regulatory guidance does not list alcohol as a formal drug-drug interaction requiring a prohibition. However, common side effects of Macrobac (such as nausea or dizziness) may be exacerbated or worsened by alcohol consumption. Caffeine is not typically listed as a regulatory interaction.

Q: Is Macrobac known to interact with hormonal birth control?

Information on Macrobac states that it may reduce the effectiveness of certain hormonal contraceptives in some women. This potential interaction is stated to increase the possibility of pregnancy or breakthrough bleeding.

Q: Can Macrobac change laboratory test results?

Abnormalities in laboratory tests have been reported. These changes can include temporary elevations in liver enzymes (ALT/AST) and bilirubin, as well as changes in white blood cell counts, such as leukopenia or neutropenia.

Q: How does the drug's purpose relate to [specific disease pathway/organ]?

Macrobac's general function is to halt the growth of susceptible bacteria by acting as a strong inhibitor of bacterial protein synthesis within the bacterial cell. This action prevents the bacteria from replicating and helps the body’s immune system manage the infection.

Q: Can taking Macrobac affect my body's natural flora (e.g., gut bacteria)?

Like nearly all antibacterial agents, Macrobac can alter the normal flora of the colon (the collection of bacteria in the gut). This change is associated with the risk of developing a serious condition known as Clostridium difficile-associated diarrhea (CDAD), which is documented in safety warnings.

Q: Does Macrobac affect blood pressure?

Official safety information primarily focuses on the serious, rare risk of QT interval prolongation and irregular heart rhythms. In certain patient populations, these cardiac effects may lead to symptoms like dizziness or fainting, which can be consistent with temporary changes in blood flow or pressure.

How should Macrobac be stored and disposed of?

Regulatory documents define mandatory conditions for Macrobac (azithromycin) storage and disposal.

Storage Requirements

Product Form Temperature Range Stability/Container Rules
Dry Forms (Tablet/Powder) 20 C to 25 C (68 F to 77 F) Store in original, tightly closed container. Protect from light and moisture.
Reconstituted (Liquid) 5 C to 30 C (41 F to 86 F) Do not freeze. Must be discarded after 10 days of mixing.

Disposal and Child Safety

All medication must be stored out of the sight and reach of children using a safety cap. Any unused portion of the liquid suspension must be safely discarded upon treatment completion or after 10 days. Disposal of expired or unused medicine should follow local regulatory requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Macrobac found in:

A-Z Index: